ArticleArthritis & rheumatology (Hoboken, N.J.)2025
Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10-Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cardiovascular Risks in Autoimmune and Inflammatory Diseases.Journal of clinical medicine · 2026Article
- Is clonal haematopoiesis the missing link between lupus and cardiovascular disease?Rheumatology (Oxford, England) · 2026Review
- IL-6 in Systemic Lupus Erythematosus: At the Intersection of Disease Activity and Cardiovascular Risk.Journal of clinical medicine · 2026Article
- Controlling cardiovascular risk factors reduces progression of atherosclerosis in a multiethnic cohort of patients with lupus.Lupus science & medicine · 2026Article
- Reactive Oxygen Species-Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Immunopathogenesis of accelerated atherosclerosis in systemic lupus erythematosus: from innate and adaptive dysregulation to clinical implications.Frontiers in immunology · 2026Review
- Accelerated immunosenescence in SLE: current evidence and clinical translation.Frontiers in immunology · 2026Review
- Systemic lupus erythematosus-driven accelerated atherosclerosis: the immune-metabolic-vascular axis and therapeutic implications.Frontiers in immunology · 2026Review
- Cardiovascular magnetic resonance as an initial screening tool in individuals with SLE and chest pain.Lupus science & medicine · 2025Article
- Combining Laboratory and Imaging Evaluation for Cardiovascular Risk Stratification in Systemic Lupus Erythematosus.Journal of clinical medicine · 2025Review
- Integrated bioinformatics, machine learning, and molecular docking reveal crosstalk genes and potential drugs between periodontitis and systemic lupus erythematosus.Scientific reports · 2025Article
- Lupus nephritis as an independent risk factor for carotid atherosclerosis in patients with systemic lupus erythematosus.Clinical rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCardiovascular disease (CVD) is a leading cause of death in individuals with systemic lupus erythematosus (SLE). We assessed atherosclerotic plaque progression and incident cardiovascular events in patients with SLE over a 10-year follow-up.
methodsWe prospectively analyzed 738 carotid ultrasound measurements (413 in patients with SLE and 325 in age/sex-matched healthy controls [HCs]) to assess new plaque development from baseline to 3-, 7-, and 10-year follow-up. Multivariate mixed-effects Poisson regression models examined potential predictors of plaque progression, including patient characteristics, Systemic Coronary Risk Evaluation, traditional cardiovascular risk factor (CVRF) target attainment, Definition of Remission in SLE (DORIS), medications, and persistent triple anti-phospholipid antibody (aPL) positivity during follow-up. Ten-year incident cardiovascular events were recorded, and univariate Cox regression analysis assessed potential associations.
resultsPatients with SLE had a 2.3-fold higher risk of carotid plaque progression than HCs (incidence rate ratio [IRR] 2.26, P = 0.002). Plaque progression risk in patients with SLE was reduced by 32% (IRR 0.68, P = 0.004) per each sustainedly attained CVRF target during follow-up, including blood pressure, lipids, smoking, body weight, and physical activity. DORIS achievement ≥75% of follow-up was associated with a 43% decrease in atherosclerosis progression risk (IRR 0.57, P = 0.033). Ten-year risk of incident cardiovascular events was higher in individuals with SLE than HCs (eight versus one event, permutation-based log-rank P = 0.036) and was associated with persistent triple aPL positivity.
conclusionPatients with SLE experience a 2.3-fold higher 10-year atherosclerosis progression risk than HCs, mitigated by sustained CVRF control and prolonged clinical remission. Persistent triple aPL positivity is associated with increased incidence of CVD events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.